| CAS NO: | 1229194-11-9 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| Molecular Weight (MW) | 738.27 |
|---|---|
| Formula | C24H30ClN7O4S.C7H8O3S.H2O |
| CAS No. | 1229194-11-9 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 100 mg/mL (135.5 mM) |
| Water: <1 mg/mL | |
| Ethanol: <1 mg/mL | |
| SMILES Code | O=C(NC1=NC=C(Cl)C=C1)C(N[C@@H]2[C@H](NC(C(S3)=NC4=C3CN(C)CC4)=O)C[C@@H](C(N(C)C)=O)CC2)=O.CC5=CC=C(S(=O)(O)=O)C=C5.[H]O[H] |
| Synonyms | DU176b; DU 176b; Edoxaban; DU-176; DU 176; DU-176b; DU176; Edoxaban tosylate monohydrate, trade name Lixiana. |
| In Vitro | In vitro activity: In human plasma, Edoxaban doubles prothrombin time and activates partial thromboplastin time at 0.256 and 0.508 μM, respectively. Cell Assay: Edoxaban tosylate monohydrate (DU-176b) inhibited FXa with Ki values of 0.561 nM for free FXa, 2.98 nM for prothrombinase, and exhibited>10 000-fold selectivity for FXa. DU-176b doubled prothrombin time and activated partial thromboplastin time in human plasma. DU-176b did not impair platelet aggregation by ADP, collagen or U46619 . |
|---|---|
| In Vivo | Oral administration of Edoxaban produces potent anti-Xa activity and high drug concentration in plasma in rats and monkeys. In vivo, Edoxaban dose-dependently inhibits thrombus formation in rat and rabbit thrombosis models. |
| Animal model | Venous stasis thrombosis model in rats and rabbits |
| Formulation & Dosage | Dissolved in 0.5% methylcellulose; 0.3–3 mg/kg (Rabbit); 0.5–12.5 mg/kg (Rat); oral gavage |
| References | J Thromb Haemost. 2008 Sep;6(9):1542-9. |
m.cnreagent.com